Ketamine can help people with treatment-resistant depression by breaking their entrenched belief systems, according to a recent paper.
Most American psychiatrists view psilocybin and ketamine as safer drugs than alprazolam (Xanax), methamphetamine, or alcohol, according to a new survey.
A psychedelic drug experience may alter people’s perspectives on death and dying in a similar way to those who have survived a near-death experience, a new study has found.
The first controlled trial of psilocybin for alcohol use disorder (AUD) reports that psilocybin-assisted psychotherapy significantly reduces the occurrence of heavy drinking days in people with AUD.
By studying human brain organoids — tissue cultures grown from stem cells that can mimic the developing brain — researchers have found that LSD regulates numerous processes related to neuroplasticity in the human brain.
By demonstrating that ketamine induces only a brief increase in dopamine and does not alter neuronal communication, a team from the University of Geneva suggests that its therapeutic use may be safe.
PSIL-001 and PSIL-002 show promising antidepressant effects without hallucinations while having improved learning and memory tendencies over a psilocybin mimic in a mouse model.
Dr Stephen Wright, a consultant in medicines development from Limber Strategic, explores the research behind ketamine.